Form 8-K - Current report:
SEC Accession No. 0001213900-25-007521
Filing Date
2025-01-28
Accepted
2025-01-28 16:00:55
Documents
14
Period of Report
2025-01-28
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0228960-8k_inmunebio.htm   iXBRL 8-K 23723
2 PRESS RELEASE DATED JANUARY 28, 2025 ea022896001ex99-1_inmunebio.htm EX-99.1 16961
  Complete submission text file 0001213900-25-007521.txt   219705

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE inmb-20250128.xsd EX-101.SCH 3015
4 XBRL LABEL FILE inmb-20250128_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE inmb-20250128_pre.xml EX-101.PRE 22359
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0228960-8k_inmunebio_htm.xml XML 3679
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 25564049
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)